HDAC10 promotes Th17 differentiation and IL-17A-driven neutrophilic airway inflammation in severe asthma.
Summary
This study identifies HDAC10 as a key epigenetic regulator of Th17 differentiation that underlies IL-17A–driven neutrophilic airway inflammation in severe asthma. Elevated HDAC10 in CD4+ T cells links epigenetic control to pathogenic Th17 polarization, nominating HDAC10 as a potential therapeutic target.
Key Findings
- HDAC10 is identified as a critical regulator of Th17 cell differentiation in severe asthma.
- Elevated HDAC10 expression is observed in CD4+ T cells in the severe asthma context (as indicated by the title and abstract lead).
- Findings implicate HDAC10 in IL-17A–driven neutrophilic airway inflammation, suggesting a druggable epigenetic target.
Clinical Implications
Pharmacologic inhibition of HDAC10 or pathway modulation could attenuate IL-17A–mediated neutrophilic inflammation in severe asthma patients poorly responsive to current biologics.
Why It Matters
It provides a mechanistic link between epigenetic regulation and Th17-driven neutrophilic asthma, a difficult-to-treat endotype with limited biologic options. Targeting HDAC10 could broaden precision therapies beyond type 2 inflammation.
Limitations
- Abstract fragment provides limited details on sample size and experimental systems
- Translational efficacy and safety of HDAC10 inhibition remain to be established in clinical studies
Future Directions
Validate HDAC10 inhibition in preclinical asthma models, define biomarkers for patient stratification, and assess safety/efficacy in early-phase clinical trials targeting neutrophilic severe asthma.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- IV - Preclinical/mechanistic evidence with disease and control comparisons; not a randomized clinical study.
- Study Design
- OTHER